BioGaia’s probiotic effective as adjunct in patients with Helicobacter pylori infection
In a double-blind, randomized and placebo-controlled study Lactobacillus reuteri Gastrus, in combination with so called quadruple therapy, was shown to improve eradication rate of infections caused by the bacterium Helicobacter pylori. Further, supplementation of Lactobacillus reuteri Gastrus significantly reduced side-effects of the treatment.
This is the first clinical study in patients with H. pylori infection, treated with quadruple therapy and supplemented by Lactobacillus reuteri Gastrus. The study enrolled 100 patients, divided into four groups. All patients received quadruple therapy and in two of the groups Lactobacillus reuteri Gastrus was added.
Treatment success was defined as a cure rate of more than 95% and this was achieved in the group treated for 14 days and supplemented by Lactobacillus reuteri Gastrus. The difference compared to the other groups was not statistically significant. However, all other groups had cure rates below 90%, which is regarded as treatment failure.
Supplementation of Lactobacillus reuteri Gastrus significantly reduced treatment-related side-effects; incidence of nausea and vomiting, abdominal pain, and bitter taste.
The study was conducted at Thammasat University Hospital in Thailand and published in the September issue of Asian Journal of Cancer Prevention. Study facts are found here.
Latest press releases from BioGaia
10.10.2019 Reduced sales due to delivery delays
08.08.2019 BioGaia AB Interim report 1 January-30 June 2019
02.07.2019 BioGaia signs exclusive agreement in Uruguay
For additional information please contact
Isabelle Ducellier, Chief Executive Officer, BioGaia, telephone: +46 8 555 293 00 +46 8 555 293 00
BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com
Tags:
